Dare Bioscience announces Notice of Award of grant from NICHD for DARE-PTB1

Dare Bioscience announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NICHD, a division of the National Institutes of Health, NIH. The award will support the clinical development of Dare‘s novel, investigational intravaginal ring, DARE-PTB1. DARE-PTB1 is designed to deliver bio-identical progesterone continuously for up to a 14-day period and is being developed as a treatment for the prevention of preterm birth in at-risk women, for which there are currently no FDA-approved treatments. “The World Health Organization estimates that globally, 13.4 million babies were born preterm in 2020, before 37 weeks of gestation and that complications from preterm birth are the leading cause of death among children under 5 years of age,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “Dare is committed to addressing persistent unmet needs in women’s health and preterm birth is a large category that could benefit from new treatment options to protect women and babies. We are grateful to the NICHD for its support and commitment to innovation in this important therapeutic area and look forward to advancing DARE-PTB1, which has the potential to be the only FDA-approved product to reduce the risk of preterm birth.”